ΜicroRNA‑889 plays a suppressive role in cell proliferation and invasion by directly targeting TAB1 in non‑small cell lung cancer

Dong,Zheng; Li,Bingchun; Wang,Xiaojuan

doi:10.3892/mmr.2019.10245

ΜicroRNA‑889 plays a suppressive role in cell proliferation and invasion by directly targeting TAB1 in non‑small cell lung cancer

Authors:
- Zheng Dong
- Bingchun Li
- Xiaojuan Wang
View Affiliations

Affiliations: Department of Outpatients, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Thoracic Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: May 15, 2019 https://doi.org/10.3892/mmr.2019.10245
Pages: 261-269

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are frequently reported to be aberrantly expressed in non‑small cell lung cancer (NSCLC) and are closely associated with aggressive tumor phenotypes. Hence, identification of cancer‑related miRNAs in NSCLC may be helpful for improving the cure rate of NSCLC treatments. miR‑889 has been demonstrated to be a novel cancer‑associated miRNA that is aberrantly expressed and plays an important role in esophageal squamous cell carcinoma and hepatocellular carcinoma. However, the exact functions and precise molecular mechanisms through which miR‑889 affects NSCLC progression are still unknown. In the present study, we report for the first time that miR‑889 expression is low in NSCLC tissues and cell lines. Clinically, low miR‑889 expression was found to be correlated with the TNM stage and distant metastasis in NSCLC patients. Functionally, miR‑889 overexpression suppressed the proliferation and invasiveness of NSCLC cells in vitro and decreased NSCLC xenograft tumor growth in mice. Furthermore, TGF‑β‑activated kinase 1‑binding protein 1 (TAB1) was confirmed as a direct target gene of miR‑889 in NSCLC cells. TAB1 was revealed to be overexpressed in NSCLC tissue samples and was inversely correlated with miR‑889 levels. Moreover, a TAB1 knockdown had effects similar to that of miR‑889 overexpression, whereas restoration of TAB1 expression counteracted the actions of miR‑889 in NSCLC cells. Overall, the present results indicated that miR‑889 inhibits the aggressive behaviors of NSCLC by directly targeting TAB1 mRNA, thus highlighting the importance of the miR‑889/TAB1 pathway in the malignant progression of NSCLC.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Qin H, Wang F, Liu H, Zeng Z, Wang S, Pan X and Gao H: New advances in immunotherapy for non-small cell lung cancer. Am J Transl Res. 10:2234–2245. 2018.PubMed/NCBI
4	Li Z, Song Y, Liu L, Hou N, An X, Zhan D, Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ. 24:1205–1213. 2015. View Article : Google Scholar : PubMed/NCBI
5	Mao M, Wu Z and Chen J: MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI
6	Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L and Kunkler I; Eurocare-4 Working Group, : Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
7	Li Z and Rana TM: Therapeutic targeting of microRNAs: Current status and future challenges. Nat Rev Drug Discov. 13:622–638. 2014. View Article : Google Scholar : PubMed/NCBI
8	Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ameres SL and Zamore PD: Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488. 2013. View Article : Google Scholar : PubMed/NCBI
10	Florczuk M, Szpechcinski A and Chorostowska-Wynimko J: miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: Current perspectives. Target Oncol. 12:179–200. 2017. View Article : Google Scholar : PubMed/NCBI
11	Xu BB, Gu ZF, Ma M, Wang JY and Wang HN: MicroRNA-590-5p suppresses the proliferation and invasion of non-small cell lung cancer by regulating GAB1. Eur Rev Med Pharmacol Sci. 22:5954–5963. 2018.PubMed/NCBI
12	Boldrini L, Giordano M, Lucchi M, Melfi F and Fontanini G: Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. Biomed Rep. 9:198–205. 2018.PubMed/NCBI
13	Pan Q, Sun L, Zheng D, Li N, Shi H, Song J, Shao G and Xu G: MicroRNA-9 enhanced cisplatin sensitivity in nonsmall cell lung cancer cells by regulating eukaryotic translation initiation factor 5A2. Biomed Res Int. 2018:17690402018. View Article : Google Scholar : PubMed/NCBI
14	Qi YJ, Zha WJ and Zhang W: MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway. Eur Rev Med Pharmacol Sci. 22:5972–5979. 2018.PubMed/NCBI
15	Lu J, Zhan Y, Feng J, Luo J and Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI
16	Fadejeva I, Olschewski H and Hrzenjak A: MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
17	Xu Y, He J, Wang Y, Zhu X, Pan Q, Xie Q and Sun F: miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP. FEBS Lett. 589:1127–1135. 2015. View Article : Google Scholar : PubMed/NCBI
18	Xie H, Zhang Q, Zhou H, Zhou J, Zhang J, Jiang Y, Wang J, Meng X, Zeng L and Jiang X: microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells. Cytotechnology. 70:513–521. 2018. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Zhu J, Li Q, He JT and Liu GY: Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance. Int J Clin Exp Pathol. 8:15801–15807. 2015.PubMed/NCBI
21	Zhou Q, Huang SX, Zhang F, Li SJ, Liu C, Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 50:2017. View Article : Google Scholar :
22	Han Y and Li H: miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC). J Thorac Dis. 10:3119–3131. 2018. View Article : Google Scholar : PubMed/NCBI
23	Li L, Sun Y, Feng M, Wang L and Liu J: Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer. Oncol Lett. 15:8915–8925. 2018.PubMed/NCBI
24	Gong H, Fang L, Li Y, Du J, Zhou B, Wang X, Zhou H, Gao L, Wang K and Zhang J: miR873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1. Oncol Rep. 39:1090–1098. 2018.PubMed/NCBI
25	Neil JR and Schiemann WP: Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res. 68:1462–1470. 2008. View Article : Google Scholar : PubMed/NCBI
26	Shuang T, Wang M, Zhou Y, Shi C and Wang D: NF-kappaB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer. Oncotarget. 8:24853–24868. 2017. View Article : Google Scholar : PubMed/NCBI
27	Isono T, Kim CJ, Ando Y, Sakurai H, Okada Y and Inoue H: Suppression of cell invasiveness by periostin via TAB1/TAK1. Int J Oncol. 35:425–432. 2009.PubMed/NCBI